John Newman
Stock Analyst at Canaccord Genuity
(1.28)
# 3,257
Out of 4,828 analysts
86
Total ratings
36%
Success rate
-14.33%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,152 → $850 | $527.78 | +61.05% | 16 | Apr 22, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.16 | +1,106.90% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $92.87 | +84.61% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $7.31 | +132.56% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.17 | +583.76% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $4.81 | +419.75% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $7.06 | +2,734.87% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $14.84 | +41.51% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $57.55 | +99.83% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.61 | +1,211.69% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $40.90 | +63.81% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $9.91 | +334.12% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $4.99 | +120.44% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.52 | +863.02% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $27.32 | +61.05% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,720 → $400 | $3.50 | +11,328.57% | 4 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $6.57 | +3,248.55% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $14.21 | +167.42% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $2.19 | +1,132.88% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $8.00 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Apr 22, 2025
Maintains: Buy
Price Target: $1,152 → $850
Current: $527.78
Upside: +61.05%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.16
Upside: +1,106.90%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $92.87
Upside: +84.61%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $7.31
Upside: +132.56%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.17
Upside: +583.76%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $4.81
Upside: +419.75%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $7.06
Upside: +2,734.87%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $14.84
Upside: +41.51%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $57.55
Upside: +99.83%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.61
Upside: +1,211.69%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $40.90
Upside: +63.81%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $9.91
Upside: +334.12%
May 9, 2024
Maintains: Buy
Price Target: $12 → $11
Current: $4.99
Upside: +120.44%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.52
Upside: +863.02%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $27.32
Upside: +61.05%
Aug 10, 2021
Downgrades: Hold
Price Target: $1,720 → $400
Current: $3.50
Upside: +11,328.57%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $6.57
Upside: +3,248.55%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $14.21
Upside: +167.42%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $2.19
Upside: +1,132.88%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $8.00
Upside: -